298 related articles for article (PubMed ID: 25652455)
1. Integrated genomic profiling, therapy response, and survival in adult acute myelogenous leukemia.
Parkin B; Ouillette P; Yildiz M; Saiya-Cork K; Shedden K; Malek SN
Clin Cancer Res; 2015 May; 21(9):2045-56. PubMed ID: 25652455
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of acquired copy-neutral loss of heterozygosity in acute myeloid leukemia.
Gronseth CM; McElhone SE; Storer BE; Kroeger KA; Sandhu V; Fero ML; Appelbaum FR; Estey EH; Fang M
Cancer; 2015 Sep; 121(17):2900-8. PubMed ID: 26033747
[TBL] [Abstract][Full Text] [Related]
3. Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor.
Wagner K; Damm F; Göhring G; Görlich K; Heuser M; Schäfer I; Ottmann O; Lübbert M; Heit W; Kanz L; Schlimok G; Raghavachar AA; Fiedler W; Kirchner HH; Brugger W; Zucknick M; Schlegelberger B; Heil G; Ganser A; Krauter J
J Clin Oncol; 2010 May; 28(14):2356-64. PubMed ID: 20368538
[TBL] [Abstract][Full Text] [Related]
4. DNMT3A Mutational Status Affects the Results of Dose-Escalated Induction Therapy in Acute Myelogenous Leukemia.
Sehgal AR; Gimotty PA; Zhao J; Hsu JM; Daber R; Morrissette JD; Luger S; Loren AW; Carroll M
Clin Cancer Res; 2015 Apr; 21(7):1614-20. PubMed ID: 25609058
[TBL] [Abstract][Full Text] [Related]
5. Acquired genomic copy number aberrations and survival in adult acute myelogenous leukemia.
Parkin B; Erba H; Ouillette P; Roulston D; Purkayastha A; Karp J; Talpaz M; Kujawski L; Shakhan S; Li C; Shedden K; Malek SN
Blood; 2010 Dec; 116(23):4958-67. PubMed ID: 20729466
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of genetic aberrations in secondary acute myeloid leukemia.
Milosevic JD; Puda A; Malcovati L; Berg T; Hofbauer M; Stukalov A; Klampfl T; Harutyunyan AS; Gisslinger H; Gisslinger B; Burjanivova T; Rumi E; Pietra D; Elena C; Vannucchi AM; Doubek M; Dvorakova D; Robesova B; Wieser R; Koller E; Suvajdzic N; Tomin D; Tosic N; Colinge J; Racil Z; Steurer M; Pavlovic S; Cazzola M; Kralovics R
Am J Hematol; 2012 Nov; 87(11):1010-6. PubMed ID: 22887079
[TBL] [Abstract][Full Text] [Related]
7. Submicroscopic deletion of 5q involving tumor suppressor genes (CTNNA1, HSPA9) and copy neutral loss of heterozygosity associated with TET2 and EZH2 mutations in a case of MDS with normal chromosome and FISH results.
Hemmat M; Chen W; Anguiano A; Naggar ME; Racke FK; Jones D; Wang Y; Strom CM; Chang K; Boyar FZ
Mol Cytogenet; 2014; 7():35. PubMed ID: 25177364
[TBL] [Abstract][Full Text] [Related]
8. Clinical and Biological Implications of Mutational Spectrum in Acute Myeloid Leukemia of FAB Subtypes M0 and M1.
Cheng Z; Dai Y; Pang Y; Jiao Y; Zhao H; Wu S; Zhang L; Zhang Y; Wang X; Wang L; Ma D; Qin T; Hu N; Zhang Y; Hu K; Zhang Q; Shi J; Fu L
Cell Physiol Biochem; 2018; 47(5):1853-1861. PubMed ID: 29961066
[TBL] [Abstract][Full Text] [Related]
9. RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.
Mendler JH; Maharry K; Radmacher MD; Mrózek K; Becker H; Metzeler KH; Schwind S; Whitman SP; Khalife J; Kohlschmidt J; Nicolet D; Powell BL; Carter TH; Wetzler M; Moore JO; Kolitz JE; Baer MR; Carroll AJ; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD
J Clin Oncol; 2012 Sep; 30(25):3109-18. PubMed ID: 22753902
[TBL] [Abstract][Full Text] [Related]
10. Clonal evolution and devolution after chemotherapy in adult acute myelogenous leukemia.
Parkin B; Ouillette P; Li Y; Keller J; Lam C; Roulston D; Li C; Shedden K; Malek SN
Blood; 2013 Jan; 121(2):369-77. PubMed ID: 23175688
[TBL] [Abstract][Full Text] [Related]
11. TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution.
Hou HA; Chou WC; Kuo YY; Liu CY; Lin LI; Tseng MH; Chiang YC; Liu MC; Liu CW; Tang JL; Yao M; Li CC; Huang SY; Ko BS; Hsu SC; Chen CY; Lin CT; Wu SJ; Tsay W; Chen YC; Tien HF
Blood Cancer J; 2015 Jul; 5(7):e331. PubMed ID: 26230955
[TBL] [Abstract][Full Text] [Related]
12. Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.
Devillier R; Mansat-De Mas V; Gelsi-Boyer V; Demur C; Murati A; Corre J; Prebet T; Bertoli S; Brecqueville M; Arnoulet C; Recher C; Vey N; Mozziconacci MJ; Delabesse E; Birnbaum D
Oncotarget; 2015 Apr; 6(10):8388-96. PubMed ID: 25860933
[TBL] [Abstract][Full Text] [Related]
13. Mutational profiling of acute myeloid leukemia with normal cytogenetics in Brazilian patients: the value of next-generation sequencing for genomic classification.
de Noronha TR; Mitne-Neto M; Chauffaille ML
J Investig Med; 2017 Dec; 65(8):1155-1158. PubMed ID: 28923882
[TBL] [Abstract][Full Text] [Related]
14. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia.
Dang H; Chen Y; Kamel-Reid S; Brandwein J; Chang H
Hum Pathol; 2013 Oct; 44(10):2038-46. PubMed ID: 23701943
[TBL] [Abstract][Full Text] [Related]
15. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia.
Thol F; Damm F; Lüdeking A; Winschel C; Wagner K; Morgan M; Yun H; Göhring G; Schlegelberger B; Hoelzer D; Lübbert M; Kanz L; Fiedler W; Kirchner H; Heil G; Krauter J; Ganser A; Heuser M
J Clin Oncol; 2011 Jul; 29(21):2889-96. PubMed ID: 21670448
[TBL] [Abstract][Full Text] [Related]
16. Analysis of acquired genomic copy number aberrations and regions of loss of heterozygosity in acute myelogenous leukemia genomes using Affymetrix SNP 6.0 arrays and supporting software tools.
Ouillette PD; Shedden KA; Li C; Malek SN
Methods Mol Biol; 2013; 973():99-119. PubMed ID: 23412786
[TBL] [Abstract][Full Text] [Related]
17. Subtype-specific patterns of molecular mutations in acute myeloid leukemia.
Rose D; Haferlach T; Schnittger S; Perglerová K; Kern W; Haferlach C
Leukemia; 2017 Jan; 31(1):11-17. PubMed ID: 27285584
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of DNMT3A mutations in patients with intermediate cytogenetic risk profile acute myeloid leukemia.
Marková J; Michková P; Burčková K; Březinová J; Michalová K; Dohnalová A; Maaloufová JS; Soukup P; Vítek A; Cetkovský P; Schwarz J
Eur J Haematol; 2012 Feb; 88(2):128-35. PubMed ID: 21967546
[TBL] [Abstract][Full Text] [Related]
19. TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.
Gaidzik VI; Paschka P; Späth D; Habdank M; Köhne CH; Germing U; von Lilienfeld-Toal M; Held G; Horst HA; Haase D; Bentz M; Götze K; Döhner H; Schlenk RF; Bullinger L; Döhner K
J Clin Oncol; 2012 Apr; 30(12):1350-7. PubMed ID: 22430270
[TBL] [Abstract][Full Text] [Related]
20. Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes.
Svobodova K; Zemanova Z; Lhotska H; Novakova M; Podskalska L; Belickova M; Brezinova J; Sarova I; Izakova S; Lizcova L; Berkova A; Siskova M; Jonasova A; Cermak J; Michalova K
Leuk Res; 2016 Mar; 42():7-12. PubMed ID: 26851439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
